Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Dec;12(1):2148563.
doi: 10.1080/22221751.2022.2148563.

Place of magistral preparations to continue the treatment if the drug is commercially stopped worldwide? A case report of a 10-year-old child with subacute sclerosing panencephalitis (SSPE) requiring inosiplex

Renan Le Cras  1 , Roseline Mazet  1 , Fanny Dubois-Teklali  2 , Cécile Sabourdy  3 , Sébastien Chanoine  1   4 , Audrey Lehmann  1 , Agathe Morin  1 , Julien Leenhardt  1   5 , Marjorie Durand  1 , Marie-Dominique Desruet  1 , Pierrick Bedouch  1   4
Affiliations
Case Reports

Place of magistral preparations to continue the treatment if the drug is commercially stopped worldwide? A case report of a 10-year-old child with subacute sclerosing panencephalitis (SSPE) requiring inosiplex

Renan Le Cras et al. Emerg Microbes Infect. 2023 Dec.

Abstract

Subacute sclerosing panencephalitis (SSPE) is a late-onset and fatal viral disease caused by persistent infection of the central nervous system by measles virus (MeV). We present the case of a 10-year-old child from South Asia affected by SSPE, stabilized with a combination of intrathecal interferon-α2b (INF-α2b) injections and oral inosiplex and how we continued the treatment when inosiplex was commercially stopped worldwide.

Keywords: Inosiplex; inosine pranobex; magistral preparation; speciality commercially stopped; subacute sclerosing panencephalitis (SSPE).

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Patient extended EEG from June 2019.
Figure 2.
Figure 2.
MRIb from June 2019 shows cortical and subcortical atrophy.
See this image and copyright information in PMC

References

    1. Leung A, Hon K, Leong K, et al. . Measles: a disease often forgotten but not gone. Hong Kong Med J. 2018;24(5):512–520. doi:10.12809/hkmj187470. - DOI - PubMed
    1. Gutierrez J, Rs I, Bs K.. Subacute sclerosing panencephalitis: an update. Dev Med Child Neurol. 2010;52(10):901–907. doi:10.1111/j.1469-8749.2010.03717.x. - DOI - PubMed
    1. Goodson J, Teleb N, Ashmony H, et al. . Progress toward measles elimination – Eastern Mediterranean Region, 2013–2019. MMWR. 2020;69(15):439–445. doi:10.15585/mmwr.mm6915a2. - DOI - PMC - PubMed
    1. Patterson M. Neurological complications of measles (Rubeola). Curr Neurol Neurosci Rep. 2020;20(2):2. doi:10.1007/s11910-020-1023-y. - DOI - PubMed
    1. Garg R, Mahadevan A, Malhotra H, et al. . Subacute sclerosing panencephalitis. Rev Med Virol. 2019;29(5):e2058. doi:10.1002/rmv.2058. - DOI - PubMed